Salabati, Mirataollah
Obeid, Anthony
Mahmoudzadeh, Raziyeh
Gupta, Omesh
Chiang, Allen
Spirn, Marc
Klufas, Michael A.
Hsu, Jason http://orcid.org/0000-0002-2761-4219
,
Article History
Received: 13 July 2021
Revised: 16 January 2022
Accepted: 18 February 2022
First Online: 1 March 2022
Declarations
:
: This study was approved by Wills Eye Hospital institutional review board and adhered to the tenets of the Declaration of Helsinki.
: Not applicable.
: M.S, A.O, R.M, and Dr. Spirn have no financial disclosures. Dr. Hsu is a consultant for IVERIC Bio (New York, NY), Gyroscope Therapeutics (London, UK), and OccuRx Pty Ltd (Melbourne, Australia). He has received grants from Roche/Genentech (San Francisco, CA), Aldeyra Therapeutics (Lexington, MA), and IVERIC Bio (New York, NY). Dr. Gupta is a consultant for Alcon. Dr. Chiang reported receiving grants from Genentech and Regeneron and is a consultant for Genentech. Dr. Klufas is a consultant for Allergan (Dublin, Ireland), Speaker and Consultant for Roche/Genentech (San Francisco, CA), and Speaker for Regeneron (Tarrytown, NY).